Literature DB >> 32006481

Retinal Nonperfusion in Proliferative Diabetic Retinopathy Before and After Panretinal Photocoagulation Assessed by Widefield OCT Angiography.

Jonathan F Russell1, Hasenin Al-Khersan1, Yingying Shi1, Nathan L Scott1, John W Hinkle1, Kenneth C Fan1, Cancan Lyu1, William J Feuer1, Giovanni Gregori1, Philip J Rosenfeld2.   

Abstract

PURPOSE: Widefield swept source optical coherence tomography angiography (WF SS-OCTA) imaging was compared with ultra-widefield (UWF) fluorescein angiography (FA) imaging to better understand changes in retinal nonperfusion before and after panretinal photocoagulation (PRP) in treatment-naïve eyes with proliferative diabetic retinopathy (PDR).
DESIGN: Prospective, observational, consecutive case series.
METHODS: Participants with treatment-naïve PDR were imaged using the SS-OCTA 12- × 12-mm scan pattern at baseline and at 1 week, 1 month, and 3 months after PRP. UWF FA was obtained at baseline and 3 months after PRP. Selected eyes were imaged using 5 SS-OCTA 12- × 12-mm scans to create a posterior pole montage, and 5 eyes also underwent SS-OCTA imaging at 6 months and 1 year. Areas of retinal nonperfusion (RNP) were drawn independently by 2 masked graders, and analysis of variance (ANOVA) tests were used to compare areas of RNP over time. Main outcome measurements consisted of areas and boundaries of RNP visualized using WF SS-OCTA and UWF FA.
RESULTS: From January 2018 through January 2019, WF SS-OCTA was performed on 20 eyes with treatment-naïve PDR from 15 patients. Areas of RNP identified on UWF FA images co-localized with RNP areas visualized on WF SS-OCTA images. There were no statistically significant changes in RNP area on WF SS-OCTA images through 3 months after PRP. Even eyes that were severely ischemic at baseline had no significant changes in RNP area 1 year after PRP.
CONCLUSIONS: RNP in PDR can be identified at baseline and imaged serially after PRP using WF SS-OCTA. Retinal perfusion in PDR does not change significantly after PRP. The ability of WF SS-OCTA to longitudinally evaluate RNP areas provides additional justification for adopting WF SS-OCTA as the sole imaging modality for clinical management of PDR.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32006481      PMCID: PMC7962743          DOI: 10.1016/j.ajo.2020.01.024

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  34 in total

1.  Optical Coherence Tomography Angiography Quantitative Assessment of Exercise-Induced Variations in Retinal Vascular Plexa of Healthy Subjects.

Authors:  Sétha Vo Kim; Oudy Semoun; Alexandre Pedinielli; Camille Jung; Alexandra Miere; Eric H Souied
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-04-01       Impact factor: 4.799

2.  Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy.

Authors:  Osama A Sorour; Almyr S Sabrosa; A Yasin Alibhai; Malvika Arya; Akihiro Ishibazawa; Andre J Witkin; Caroline R Baumal; Jay S Duker; Nadia K Waheed
Journal:  Int Ophthalmol       Date:  2019-05-22       Impact factor: 2.031

3.  Improved Macular Capillary Flow on Optical Coherence Tomography Angiography After Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.

Authors:  Amani A Fawzi; Alaa E Fayed; Robert A Linsenmeier; Jing Gao; Fei Yu
Journal:  Am J Ophthalmol       Date:  2019-05-10       Impact factor: 5.258

4.  Longitudinal Wide-Field Swept-Source OCT Angiography of Neovascularization in Proliferative Diabetic Retinopathy after Panretinal Photocoagulation.

Authors:  Jonathan F Russell; Yingying Shi; John W Hinkle; Nathan L Scott; Kenneth C Fan; Cancan Lyu; Giovanni Gregori; Philip J Rosenfeld
Journal:  Ophthalmol Retina       Date:  2018-11-24

5.  Signal Strength Reduction Effects in OCT Angiography.

Authors:  Jeffrey J Yu; Acner Camino; Liang Liu; Xinbo Zhang; Jie Wang; Simon S Gao; Yali Jia; David Huang
Journal:  Ophthalmol Retina       Date:  2019-05-08

6.  Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.

Authors:  Aude Couturier; Pierre-Antoine Rey; Ali Erginay; Carlo Lavia; Sophie Bonnin; Bénédicte Dupas; Alain Gaudric; Ramin Tadayoni
Journal:  Ophthalmology       Date:  2019-06-26       Impact factor: 12.079

7.  Effect of panretinal photocoagulation on retinal blood flow in proliferative diabetic retinopathy.

Authors:  J E Grunwald; C E Riva; A J Brucker; S H Sinclair; B L Petrig
Journal:  Ophthalmology       Date:  1986-05       Impact factor: 12.079

8.  OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema.

Authors:  Yi-Ting Hsieh; Minhaj Nur Alam; David Le; Chia-Chieh Hsiao; Chang-Hao Yang; Daniel L Chao; Xincheng Yao
Journal:  Ophthalmol Retina       Date:  2019-05-07

9.  Controlling for Artifacts in Widefield Optical Coherence Tomography Angiography Measurements of Non-Perfusion Area.

Authors:  Lucas R De Pretto; Eric M Moult; A Yasin Alibhai; Oscar M Carrasco-Zevallos; Siyu Chen; ByungKun Lee; Andre J Witkin; Caroline R Baumal; Elias Reichel; Anderson Zanardi de Freitas; Jay S Duker; Nadia K Waheed; James G Fujimoto
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

10.  Diurnal variation of choriocapillaris vessel flow density in normal subjects measured using optical coherence tomography angiography.

Authors:  Salman Sarwar; Muhammad Hassan; Mohamed K Soliman; Muhammad Sohail Halim; Mohammad Ali Sadiq; Rubbia Afridi; Aniruddha Agarwal; Diana V Do; Quan Dong Nguyen; Yasir J Sepah
Journal:  Int J Retina Vitreous       Date:  2018-10-10
View more
  7 in total

1.  Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.

Authors:  Irini Chatziralli; Eleni Dimitriou; George Theodossiadis; Dimitrios Kazantzis; Panagiotis Theodossiadis
Journal:  Acta Diabetol       Date:  2020-05-29       Impact factor: 4.280

2.  Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time.

Authors:  Paolo S Silva; Dennis M Marcus; Danni Liu; Lloyd Paul Aiello; Andrew Antoszyk; Michael Elman; Scott Friedman; Adam R Glassman; Joseph M Googe; Lee Merrill Jampol; Daniel F Martin; Michele Melia; Carin M Preston; Charles C Wykoff; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2022-10-01       Impact factor: 8.253

3.  WIDE-FIELD SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF DIABETIC TRACTIONAL RETINAL DETACHMENTS BEFORE AND AFTER SURGICAL REPAIR.

Authors:  Jonathan F Russell; Nathan L Scott; Justin H Townsend; Yingying Shi; Giovanni Gregori; Ashley M Crane; Harry W Flynn; Jayanth Sridhar; Philip J Rosenfeld
Journal:  Retina       Date:  2021-08-01       Impact factor: 3.975

4.  Aqueous Humor Analyses in Patients with Diabetic Retinopathy Who Had Undergone Panretinal Photocoagulation.

Authors:  Jin-Woo Kwon; Jusang Oh
Journal:  J Diabetes Res       Date:  2022-06-20       Impact factor: 4.061

Review 5.  Artificial intelligence for improving sickle cell retinopathy diagnosis and management.

Authors:  Sophie Cai; Ian C Han; Adrienne W Scott
Journal:  Eye (Lond)       Date:  2021-05-06       Impact factor: 4.456

6.  Retinal and Choroidal Vascular Perfusion and Thickness Measurement in Diabetic Retinopathy Patients by the Swept-Source Optical Coherence Tomography Angiography.

Authors:  Tingting Liu; Wei Lin; Genggeng Shi; Wenqi Wang; Meng Feng; Xiao Xie; Tong Liu; Qingjun Zhou
Journal:  Front Med (Lausanne)       Date:  2022-03-18

Review 7.  Ultrawide Field Imaging in Diabetic Retinopathy: Exploring the Role of Quantitative Metrics.

Authors:  Mohamed Ashraf; Jerry D Cavallerano; Jennifer K Sun; Paolo S Silva; Lloyd Paul Aiello
Journal:  J Clin Med       Date:  2021-07-27       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.